Has the Norwegian Biotech Industry valuation changed over the past few years?

Investors are pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically. The industry's 3-year average PS ratio 42.7x is higher than the industry's current PS ratio of 25.6x.

How does Norwegian Biotech compare with similar industries?

There is insufficient data on the sub-industries of this industry.

Norwegian (OSEAX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Thu, 30 Jun 2022	kr19.5b	kr769.9m	-kr1,381,086,832.00	43.5x
Sat, 28 May 2022	kr22.0b	kr1.1b	-kr1,031,087,618.00	39.8x
Mon, 25 Apr 2022	kr25.5b	kr1.0b	-kr986,992,070.00	41x
Wed, 23 Mar 2022	kr26.2b	kr2.7b	kr396.9m	9.7x
Fri, 18 Feb 2022	kr27.9b	kr2.7b	kr468.8m	10.5x
Sun, 16 Jan 2022	kr36.5b	kr2.2b	kr37.2m	37.7x
Tue, 14 Dec 2021	kr38.5b	kr2.2b	kr83.3m	41.5x
Thu, 11 Nov 2021	kr38.3b	kr2.6b	kr474.7m	15.4x
Sat, 09 Oct 2021	kr37.5b	kr2.6b	kr473.4m	15x
Mon, 06 Sep 2021	kr41.7b	kr2.6b	kr508.1m	18.7x
Wed, 04 Aug 2021	kr37.1b	kr2.6b	kr508.1m	15.2x
Sat, 08 May 2021	kr41.3b	kr2.5b	kr545.4m	18.5x
Tue, 09 Feb 2021	kr35.5b	kr2.5b	kr675.0m	15.8x
Mon, 02 Nov 2020	kr26.9b	kr235.2m	-kr1,189,469,577.00	32.6x
Thu, 06 Aug 2020	kr22.8b	kr252.6m	-kr1,172,636,276.33	30.2x
Sun, 10 May 2020	kr17.5b	kr268.6m	-kr1,101,468,269.79	56.1x
Sat, 01 Feb 2020	kr15.8b	kr233.9m	-kr1,101,022,953.96	2.5x
Tue, 05 Nov 2019	kr7.4b	kr189.6m	-kr1,043,344,318.00	n/a
Fri, 09 Aug 2019	kr6.8b	kr176.3m	-kr1,022,520,318.00	n/a


NO Market	2.78%
Healthcare	0.50%
Biotech	-2.02%
Biotech	-2.02%

Company	Last Price	7D	1Y	Valuation
EXTX EXACT Therapeutics	kr19.00	2.7% +kr15.0m	-18.8%	PS10982.7x
TRVX Targovax	kr1.03	4.5% +kr8.3m	-88.0%	PB0.5x
BGBIO BerGenBio	kr11.27	0.8% +kr8.0m	-53.2%	PS1292.4x
ABS Arctic Bioscience	kr14.20	1.4% +kr4.9m	-34.0%	PS16.1x
PCIB PCI Biotech Holding	kr3.93	0.8% +kr1.1m	-85.5%	PS25x

Jun 06

Lytix Biopharma as Announces That LTX-315 with Adoptive Cell Therapy Has Been Shown to Generate Tumor-Specific T Cells and Stabilize the Disease in Patients with Metastatic Soft Tissue Sarcoma (STS)

Lytix Biopharma AS announces data from its ATLAS-IT-04 trial in patients with progressive metastatic soft tissue sarcoma (STS). The data from this Phase II proof of concept study shows that LTX-315 in combination with Adoptive Cell Therapy (ACT) was able to stabilize the disease in 3 out of 4 fully treated patients in this hard-to-treat patient population, and that the LTX-315 treatment generated tumor-specific T cells. The data is presented June 5th, 2022, as a poster at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, Chicago, IL, U.S.A. The ATLAS-IT-04 trial was an open label, exploratory, Phase II trial assessing the effect of LTX-315 when used in combination with ACT in patients with metastatic STS. ACT with tumor infiltrating lymphocytes (TILs) is a potent treatment that can induce complete and durable tumor regression as documented in patients with melanoma. The use of ACT with TILs for patients with advanced STS has not previously been reported. Patients with advanced stages of STS have few effective treatment options and respond poorly to current treatment as well as to immunotherapy tested in clinical trials. The trial design of ATLAS-IT-04 included intratumoral injections of LTX-315 ahead of surgical removal of tumors, followed by in vitro expansion of T cells as the first step. In a second step, the expanded T cells were infused back to the patients and the effect of LTX-315 on the tumor microenvironment was assessed. LTX-315 is a first-in-class non-viral oncolytic molecule, representing a new and superior in situ therapeutic vaccination principle to boost the clonal expansion of T cells that kill tumor cells through a targeted immune response. In a recent Phase I/II study LTX-315 has been shown to increase TILs in malignant solid tumors after intratumoral injection. The immune response data from the ATLAS-IT-04 trial demonstrates that the treatment induce both new and tumor-specific T cells which provides proof to the concept that LTX-315 generates an immune response that targets the tumor. Moreover, the data shows that LTX-315 induce expansion of a heterogenous pool of T-cell clones in blood, and a pool of these are also present in tumor tissue after treatment.

Norwegian (OSEAX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

ULTI

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

TRVX

Targovax ASA Announces that the FDA Grant Authorization to Initiate Clinical Trials with the Enhanced TG01 RAS Vaccine in the USA

NYKD

Nykode Therapeutics Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial

NANOV

Nordic Nanovector to Seek Regulatory Feedback Following Its Preliminary Review and Independent Data Evaluation of Paradigme, Its Phase 2B Trial with Betalutin in R/R Follicular Lymphoma

BGBIO

Chairman of the Board recently bought kr268k worth of stock

EXTX

EXACT Therapeutics as Announces Board Changes

LYTIX

Lytix Biopharma as Announces That LTX-315 with Adoptive Cell Therapy Has Been Shown to Generate Tumor-Specific T Cells and Stabilize the Disease in Patients with Metastatic Soft Tissue Sarcoma (STS)

ABS

Global Medical Director recently bought kr101k worth of stock

PCIB

Insufficient new directors

HBC

Chief Executive Officer recently bought kr170k worth of stock

AZT

Here's What Analysts Are Forecasting For ArcticZymes Technologies ASA (OB:AZT) After Its First-Quarter Results